The Michigan Radiation Oncology Quality Consortium (MROQC) investigates the most appropriate use of intensity modulated radiation therapy for breast and lung cancer patients. The goal is to minimize side effects and determine the types of patients who would be most likely to benefit from this technology.
For more information, go to mroqc.org.
Quality improvement initiative results include:
- An increase in the use of accelerated whole breast irradiation in eligible patients from 36 percent to 85 percent since 2014, with a goal of 85 percent consortium-wide.
- An increase in the use of motion assessment in lung cancer patients from 53 percent to 86 percent since 2014, with a goal of 90 percent consortium-wide.